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Preconditioning refers to a procedure by which a single noxious stimulus below the
threshold of damage is applied to the tissue in order to increase resistance to the
same or even different noxious stimuli given above the threshold of damage. Hypoxic
preconditioning relies on complex and active defenses that organisms have developed
to counter the adverse consequences of oxygen deprivation. The protection it confers
against ischemic attack for instance as well as the underlying biological mechanisms
have been extensively investigated in animal models. Based on these data, hypoxic
conditioning (consisting in recurrent exposure to hypoxia) has been suggested a potential
non-pharmacological therapeutic intervention to enhance some physiological functions
in individuals in whom acute or chronic pathological events are anticipated or existing.
In addition to healthy subjects, some benefits have been reported in patients with
cardiovascular and pulmonary diseases as well as in overweight and obese individu-
als. Hypoxic conditioning consisting in sessions of intermittent exposure to moderate
hypoxia repeated over several weeks may induce hematological, vascular, metabolic,
and neurological effects. This review addresses the existing evidence regarding the use
of hypoxic conditioning as a potential therapeutic modality, and emphasizes on many
remaining issues to clarify and future researches to be performed in the field.
Keywords: intermittent hypoxia, conditioning, therapeutics, dose, humans, murines
Introduction
Intermittent hypoxia (IH) is well known in clinical physiopathology as a central characteristic
of obstructive sleep apnea syndrome (OSAS). Chronic cyclical (30–90 s cycles) severe hypoxia is
recognized as amajormechanismunderlying the adverse systemic consequences ofOSAS.Desatura-
tion–reoxygenation sequences lead to oxidative stress and the production of reactive oxygen species
(ROS) (1). Increased ROS levels lead to increased expression of adhesion molecules (2), activation
of leukocytes (3), and production of systemic inflammation (4). Oxidative stress, systemic inflam-
mation, and sympathetic activation underlie marked cardiovascular and metabolic morbidities in
OSAS. There are now convincing data regarding the association between hypertension, arrhythmias,
stroke, coronary heart disease, increased cardiovascular mortality, metabolic dysregulation, and
OSAS (5). Nocturnal exposure to IH in healthy subjects has been shown to increase daytime arterial
blood pressure and sympathetic activity (6, 7). OSAS should therefore be considered as a systemic
disease with IH leading to deleterious consequences throughout the organism.
Several arguments suggest, however, that hypoxic exposure may also lead to some positive adap-
tations of the human body, able to protect him from several pathological conditions. Athletes have
been using hypoxic training as a training strategy for decades, with increasingly complex methods
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and technology aimed at improving sport performances (8). Inter-
estingly, some epidemiologic data suggest that living at moderate
altitudemay be associatedwith lower prevalence of obesity (9–11).
Voss et al. (11), for instance, found in a USA-wide representative
sample of >400,000 subjects that after controlling for urban-
ization, temperature category, and behavioral and demographic
factors, male and female Americans living<500m above sea level
had 5.1 [95% confidence interval (CI): 2.7–9.5] and 3.9 (95% CI:
1.6–9.3) times the odds of obesity, respectively, compared to their
counterparts living >3000m. Although IH is essentially consid-
ered as a deleterious factor in OSAS, some results suggest that
moderate OSAS may be associated with some protection against
ischemic-reperfusion events (12, 13). IHmay in this case enhance
the number and function of endothelial progenitor cells, promot-
ing angiogenesis and coronary collateral vessels for instance (14).
The potential protective effect of IH exposure also arose from
clinical studies, suggesting that patients who had strokes preceded
by transient ischemic attacks (implying somehypoxic stress) in the
same vascular territory often had less severe deficits at the onset
of their stroke and more favorable outcomes (15, 16).
A number of animal studies have described over the past
decades the effect of ischemic and hypoxic preconditioning,
demonstrating that some pattern and severity of hypoxic exposure
can provide protective effects against various deleterious stimuli.
While these experimental studies focusing on preconditioning
mostly looked at the effect of acute hypoxic conditioning (i.e., a
single session of hypoxic exposure) to induce protection over a
limited period of time, they opened perspectives regarding the
induction of a more prolonged state of protection based on recur-
rent hypoxic exposure, i.e., hypoxic conditioning (or intermittent
hypoxic training). After summarizing the principles of hypoxic
(pre)-conditioning, this review will present the available evidence
regarding the use of hypoxic conditioning for several patholog-
ical conditions as well as highlight the remaining questions and
perspectives for future research.
Principle of Hypoxic (Pre)-Conditioning
Preconditioning is a procedure by which a potentially deleterious
stimulus is applied near to but below the threshold of damage to
the organism. Shortly after this preconditioning procedure or after
some time delay, tissues and organs can develop resistance or tol-
erance to the same or similar noxious stimuli, therefore preventing
or reducing the damage it may induce. The preconditioning phe-
nomenon relies on the basic principle that organisms have devel-
oped complex and active defenses to counter adverse conditions
such as starvation and oxygen deprivation. Many stimuli, such as
ischemia, hypoxia, hypothermia, and pharmacological agents can
induce a preconditioning response and modify the responses of
the organism to subsequent stress conditions. To identify endoge-
nous mechanisms of protection and repair, and to potentially
use these mechanisms therapeutically, preconditioning strategies
have been tested over the past decades.
In 1986, Murry et al. (17) first described the principle of
ischemic preconditioning. Four cycles of 5-min ischemia followed
by short episodes of reperfusion in dogs resulted in a remark-
able reduction of infarct size following a subsequently induced
myocardial ischemia-reperfusion (I/R) injury. A few years later,
Shizukuda et al. (18) were able to demonstrate similar protective
effects of hypoxia pre-treatment and ischemic preconditioning
and introduced the term hypoxic preconditioning. Both the per-
fusion of dog hearts with severely hypoxic blood and a short pre-
insult period of ischemia of 5min followed by 10min of reperfu-
sion subsequently resulted in a comparable reduction of the size
of an infarct induced by 60min of coronary artery occlusion (18).
Most of the studies demonstrating IH-induced preconditioning
effects in the heart and brain are derived from animal models
mimicking OSAS. In a series of studies from our laboratory (19–
21), rats were subjected to various paradigms (i.e., pattern and
severity of exposure) of acute hypoxia. Compared to normoxia,
intermittent moderately severe hypoxia (inspiratory oxygen frac-
tion, FiO2= 10%) applied for 4 h improved the tolerance of the
myocardium to ischemia and induced delayed preconditioning by
reducing infarct size in isolated rat hearts. Conversely, constant
moderately severe hypoxia for 4 h had no protective effect while
applying a more severe IH (FiO2= 5%) enhanced infarct size,
clearly demonstrating that the effect of IH on infarct size was
dependent on the pattern (intermittent versus continuous) and
severity (10 versus 5% FiO2) of hypoxic exposure (20) (Figure 1).
In addition to myocardial protection, similar protective effects of
hypoxic preconditioningwere also described in the brain, with the
discoveries that pre-exposure to hypoxia can prolong anoxic sur-
vival by preserving brain metabolism (22), that brain can adapt to
anoxia by hypoxic pre-exposure (23), and finally with the descrip-
tion of ischemic preconditioning against ischemic neuronal dam-
age (24). It should be emphasized that most IH exposure used to
trigger hypoxic preconditioning induces hypocapnic hypoxemia
(because of the hypoxia-induced hyperventilation), while OSAS
FIGURE 1 | Infarct size (I) expressed as a percentage of ventricles (V)
assessed after a no-flow global ischemia (30min)-reperfusion
(120min) sequence in groups of mice exposed to 4h of normoxia (S),
intermittent hypoxia (IH, FiO2=5 or 10%), or chronic hypoxia (CH).
*P<0.05 versus the other groups; §P<0.05 versus S; 4 h, and IH10, 4 h.
From Ref. (20).
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induces hypercapnic hypoxemia. Hence, the differences between
the deleterious consequences of OSAS described earlier and the
protective effects of hypoxic preconditioningmight result not only
from the severity of the IH stress but also from the differences in
CO2 levels between both conditions.
Most of the studies mentioned above describe a precondition-
ing phenomenon consisting in acute ischemic or hypoxic exposure
(i.e., a single exposure to hypoxia), leading to protection against
subsequent ischemic insult for some hours or days only. However,
several experimental studies suggest that conditioning strategies
using repetitive exposure (several hypoxic exposures over days or
weeks) to appropriate doses of hypoxia may induce a prolonged
and sustained state of protection.
Hence, as early as 1960, the reported lower incidence of
myocardial infarction in people living at high altitude (25) led
to animal models describing protective effects of repetitive expo-
sure to IH on the myocardium, more than 10 years (26) before
the breakthrough study of Murry et al. on acute ischemic pre-
conditioning (17). The chronic intermittent hypobaric hypoxia
model was first designed to reproduce the beneficial effects of
adaptation to high altitude. It was characterized by daily expo-
sure to a sustained (4–8 h) period of hypobaric (5000–7000m)
hypoxia followed by a return to normoxic conditions. Intermit-
tence was provided by repetition of this stimulus over several days.
Thus, rats exposed to simulated high altitude (5000m, 8 h/day,
5 days/week, 24–32 days) have reduced I/R-induced myocardial
necrosis (27), ventricular arrhythmia (28–30), and apoptosis (31).
Overall, chronic intermittent hypobaric hypoxia exposure has
consistently been shown to improve cardiac ischemic tolerance,
with less adverse effects than chronic continuous hypoxia (32, 33).
Most importantly, the myocardial infarct size-limiting effect of
chronic intermittent hypobaric hypoxia appears to have a much
longer time-span than that obtained with acute preconditioning
protocols (34).
Recent studies have been investigating the protective effects
of chronic repeated exposure to normobaric hypoxia. Hence,
Stowe et al. (35) showed in mice that hypoxic conditioning by
repeated hypoxia sequences (2 or 4 h, FiO2= 8 or 11%) for 2weeks
protects against transient focal stroke for the following 8weeks,
together with reduced post-ischemic inflammation. A series of
repetitive hypoxic conditioning stimuli (2 h, FiO2= 8 or 11%) for
12 days can induce neuroprotection in the retina that lasts up to
4weeks (36). Repetitive conditioning stimuli may therefore be an
attractive option to provide prolonged protection.
Other results also suggest that intermittent hypoxic exposure
may improve regeneration following an organ insult. Hence,
conditioning strategies applied after focal ischemia and reperfu-
sion (i.e., post-conditioning) have been proposed as a protective
approach to lessen injury and improve recovery. In dogs, following
lethal ischemia of the left anterior descending artery, it has been
shown that three cycles of 30 s reperfusion and 30 s occlusion at
the start of reperfusion reduced myocardial infarct size by 44%
(37). Recovery may not only be enhanced by intervention in
the minutes following acute ischemia but also by interventions
applied over the days following the insult. For instance, in rats
after ischemic brain injury IH exposure for 7 dayswithmoderately
reduced inspiratory oxygen fraction (FiO2= 12%, 4 h per day)
has been shown to enhance neurogenesis and to preserve spatial
learning and memory (38). Hence, while acute preconditioning
to protect against a subsequent ischemic insult occurring during
the following hours has been originally described andmost deeply
investigated, alternative conditioning strategies include repetitive
conditioning stimuli in order to provide prolonged state of pro-
tection or regeneration. Such strategies may not only apply to
protection or recovery associated with ischemic insults but also
to other cardiovascular, metabolic, and neurological disorders
(see below). Hypoxic exposure can be used to trigger condi-
tioning phenomenon when applied at rest but also when com-
bined with exercise (exercise training in hypoxia, see below) or
with hyperoxic exposure [intermittent hypoxic–hyperoxic train-
ing, e.g., Ref. (39, 40)].
Potential Mechanisms Triggered by
Hypoxic Conditioning
As mentioned above, the time-course of protection afforded by
hypoxic conditioning can be extended by increasing the dura-
tion of the conditioning protocol (34). This could be due to the
recruitment of additional protective mechanisms in response to
repetitive exposure. In this section, we review the various mech-
anisms involved in the beneficial effects of both acute and long-
term IH exposure in order to propose a potential explanation for
this phenomenon.
Whether acute or repeated, hypoxic conditioning appears to
be accompanied by substantial changes in gene expression. A
crucialmediator of this genomic response is the hypoxia-inducible
factor 1 (HIF-1) transcription factor, a key regulator of cellular
oxygen homeostasis. HIF-1 is a complex protein composed of
two subunits, the cytosolic HIF-1α (O2-sensitive) subunit and the
nuclearHIF-1β subunit, which dimerize in the nucleus to form the
functional HIF-1 transcription factor and activate gene transcrip-
tion. In well-oxygenated cells, proline hydroxylation of the HIF-
1α subunit by prolyl-hydroxylase enzymes (PHDs) leads to ubiq-
uitination and proteasomal degradation. In sustained hypoxic
conditions, HIF-1α hydroxylation and subsequent degradation
are reduced because of substrate (O2) limitation, so that HIF-1α
translocates to the nucleus to bind HIF-1β and activate the tran-
scription of various genes geared to maintain cellular homeostasis
under reduced oxygen availability. Upon return to normoxic con-
ditions, cytosolic levels of HIF-1α rapidly decline and the effects
of HIF-1 decrease (41).
The major role of HIF-1 and its target genes in
ischemic/hypoxic conditioning is evidenced by the complete loss
of ischemia-induced cardioprotection in mice with partial HIF-1
deficiency (42). Similarly, we have shown that prevention of HIF-
1 activation abolished the delayed cardio-protection provided by
acute IH in the rat (21), and a recent study reported that HIF-1
inhibition prevented the acute IH-induced neuroprotection (43).
Nitric oxide (NO) is known to play a critical role in precon-
ditioning and cytoprotection through its vasodilating effect as
well as for its ability to modulate mitochondrial function (44).
Others and we have shown that the inducible nitric oxide synthase
(iNOS) gene, a HIF-1 target gene, is up-regulated along with HIF-
1 activation in response to acute exposure to IH (21, 45) and
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that NO is involved in its delayed protective effects (20, 21, 46).
In addition to HIF-1, GATA-4, a transcription factor involved
in the regulation of apoptosis, has been shown to activate the
gene expression of the anti-apoptotic proteins, bcl-2 and bcl-x(L),
following acute IH exposure in mice (47). Finally, well-known
mediators of classic ischemic preconditioning are also triggered
by acute IH exposure. Hence, we have evidenced the role of ATP-
dependent potassium (KATP) channels (20) and of stress-activated
kinases such as protein kinase C (PKC), p38 mitogen-activated
protein kinase (MAPK), and extracellular signal-regulated kinase
(ERK1/2) (19) in the cardio-protection induced by a 4-h exposure
to moderately severe (FiO2= 10%) IH.
Although the effects of HIF-1 rapidly decline upon re-
oxygenation following sustained hypoxia, we have found that IH
induces a strong and sustained whole-body activation of HIF-1
that persists after IH exposure. This can be explained by the oxida-
tive stress produced by the repetition of oxygenation-desaturation
sequences. Indeed, ROS are potent inductors of HIF-1 by increas-
ing the expression of the HIF-1α protein and by inhibiting its
PHD-dependent degradation (41). Repeated IH exposure could
thus result in activation of additional cytoprotective genes that
are not or insufficiently expressed upon sustained hypoxia or
short-term IH exposure.
Consequently, in addition to involving the iNOS gene (48) and
the KATP channels (49), chronic IH has also been shown to pro-
mote the expression of the erythropoietin (EPO) gene (50). EPO
is well recognized as a potent protective agent against ischemic
injury since its binding to EPO receptors activates numerous pro-
tective signaling pathways, such as Janus kinase 2 (JAK2)/signal
transducer and activator of transcription 3 (STAT3) pathway, the
phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) path-
way, and the MAPK pathway, all known to confer cytoprotection,
in particular cardioprotection (51), nephroprotection (52), and
neuroprotection (53). A recent study confirms the pivotal role of
the JAK2/STAT3 pathway in a cardioprotective chronic IHmodel.
Activation of the pathway by a 4-week exposure to chronic IH was
directly linked to improvement of functional recovery upon reper-
fusion via maintenance of intracellular Ca2+ homeostasis and
of mitochondrial function (54). The involvement of other EPO-
related signaling pathways, such as the PI3K/Akt pathway, has
also been confirmed in the infarct size-sparing effects of chronic
IH exposure (55, 56). Interestingly, we observed that (PI3K)/Akt
pathway was not involved in the cardioprotection afforded by
acute IH exposure (19). This is in agreement with the notion that
long-term exposure can trigger additional protectivemechanisms,
particularly through EPO production. In accordance, EPO has
been shown to play a pivotal role in the cerebral infarct size
reduction provided by chronic IH post-conditioning in mice (57).
Among the other tissue protective genes upregulated by HIF-1
upon long-term hypoxic exposure are genes encoding angiogenic
growth factors and cytokines, such as vascular endothelial growth
factor (VEGF), angiopoietins, and platelet-derived growth factors
(41). In agreement, rats exposed to chronic IH display a 1.5-
fold increase in left ventricular capillary, a higher pre-ischemic
coronary flow of isolated hearts and an improved recovery after
I/R (58). We also found an increased myocardial capillary density
and VEGF expression in rats exposed to 35 days of normobaric
IH (59). This increase in angiogenesis might not only contribute
to the cytoprotection conferred by repeated hypoxic conditioning
but could also explain why the protection lasts longer than that
obtained with acute conditioning protocols.
Finally, other important mediators of the cytoprotective effects
of chronic IH are heat stress proteins (HSP), in particular the
HSP70 family, also regulated by HIF-1 (60). HSP70 are thought
to act as molecular chaperones to repair or remove proteins dena-
tured by stresses such as I/R, leading to protection and/or restora-
tion of cell function (61). Thus, hypoxic preconditioning has
been shown to reinforce HIF-1-dependent HSP70 signaling with
beneficial effects on ischemic renal apoptosis and autophagy (60)
as well as occurrence of I/R-induced ventricular arrhythmias (62).
Hypoxic Conditioning in Healthy Subjects
Intermittent hypoxia training is recognized by the sportsmedicine
community as a potentially useful strategy to enhance exercise
performance in athletes (8). Living or training under hypoxic con-
ditionsmay improve exercise performance probably by promoting
hematological and muscle adaptations and without eliciting the
detrimental effects of chronic hypoxic exposure. Several studies
focusing on these types of hypoxic training programs reported
promising results especially in terms of performance gain, but
some debates remain regarding the usefulness of IH training in
athletes (63). Beyond the enhancement of physical performances
(8, 64), and on the basis of some established protective preclinical
effects of IH, hypoxic conditioning in healthy subjects has been
evaluated as a potential useful intervention to improve some
physiological functions and risk factors for acute and chronic
diseases.
Hematology
As demonstrated following environmental exposure to sustained
hypobaric hypoxia (e.g., altitude) (65), moderate IH exposure
can also trigger hematological changes. Nine days of hypo-
baric IH exposure (simulated altitude ranging from 4000 to
5500m, 3–5 h/day) induced a significant increase in hematocrit,
red blood cell count, reticulocytes, and hemoglobin concentra-
tion (66). Hellemans (67) showed that normobaric IH sessions
(5min FiO2= 9–10% alternating with 5min of normoxia, 60min
per day, twice a day, for 18 days) in 10 elite endurance ath-
letes triggered significant increases in reticulocyte count (30%),
hemoglobin (4%), and hematocrit (5%). Hence, while continu-
ous and prolonged exposure to hypoxia triggers significant and
sustained hematological effects, IH protocols with substantially
lower total hypoxic doses seem to be sufficient to enhance ery-
thropoiesis (68).
Ventilation
Beyond the well-known increase in hypoxic ventilatory response
associatedwith prolonged hypoxic exposure, IHmay elicit specific
forms of respiratory plasticity. Briefly, respiratory plasticity is
defined as a persistent change in the neural pathways and synapses
(morphology and/or function) of the nervous system involved in
generating respiratory activity, in response to prior experience
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(69). In the context of IH, respiratory plasticity is referred to long-
term facilitation (LTF) (70). Ten brief bouts (3min) of isocap-
nic hypoxia (FiO2= 8%), interspersed with 5min of normoxia
applied during non-rapid eye movement sleep in healthy subjects
(71) and snoring individuals (72) reduced upper airway resistance,
suggesting LTF of upper airway dilatators and more particularly
hypoglossal muscle LTF (73). Hence, based on these results sug-
gesting that IH exposuremay trigger respiratory plasticity in phys-
iological conditions, translating the use of hypoxic conditioning to
pathological conditions seems to be relevant and will be discussed
later in this review.
Cardiovascular System
In contrast to the harmful effects of chronic IH upon the car-
diovascular system observed in severe OSAS, moderate IH may
induce some positive cardiovascular adaptations. Shatilo et al.
(74) submitted two groups of healthy 60- to 74-year-old men
(14 physically active, 21 sedentary) to normobaric IH (cycles of
5min hypoxia, FiO2= 12%, followed by 5min normoxia, repeated
four times a day during 10 days). In sedentary subjects only, IH
induced a decrease in blood pressure of 7.9 3.1mmHg and an
increase in submaximal exercise capacity (workload at anaero-
bic threshold+ 12.7%), highlighting the positive cardiovascular
effects of hypoxic conditioning in healthy older inactive men.
Supporting these results, and by combining hypoxic exposure
and exercise, Bailey et al. (75) exposed, in a randomized con-
trolled and double blind manner, 34 physically active subjects to
either a normoxic (n= 14, FiO2 20.9%) or a hypoxic (n= 18,
FiO2 16%) training (cycling three times per week for 20–30min
at 70–85% ofmaximumheart rate previously determined either in
normoxia or hypoxia, during 4weeks). Hypoxic exercise training
only significantly decreased maximal exercise systolic blood pres-
sure by 10 9mmHg and increased maximal oxygen uptake by
0.47 0.77 L/min.
Increased arterial stiffness is known to be associated with an
increase in the risk of occurrence of cardiovascular events (76).
The beneficial aspects of combining hypoxic exposure and exer-
cise training upon arterial stiffness have been studied in women.
Sixteen postmenopausal women were randomly allocated either
to a hypoxic exercise group (n= 8, hypobaric hypoxic chamber,
2000m, 2 h exposure per session, 4 days per week, during 8weeks)
or a normoxic exercise group (n= 8, 2 h exposure per session,
4 days per week, during 8weeks). Exercise (aquatic exercises) was
performed in both groups under normoxic or hypoxic condi-
tions at an intensity of 50% peak oxygen uptake for 30min.
Mild hypoxic exposure combined with exercise training signifi-
cantly reduced arterial stiffness in postmenopausal women, while
exercise training performed at the same relative intensity under
normoxic conditions did not induce any change (77). These
results corroborate the work of Vedam et al. (78) showing an
NO-mediated reduction in arterial stiffness among healthy adults
men exposed to a single hypoxic session (n= 12, arterial oxyhe-
moglobin saturation 80% during 20min) compared to subjects
evaluated under room-air conditions.
Taken together, these results confirm the potential positive
effects of hypoxic conditioning on the cardiovascular function in
healthy subjects, including older individuals and females.
Metabolic Status
Preclinical data indicate a potential beneficial impact of moderate
IH exposure on blood glucose and cholesterol levels, mitochon-
drial enzyme activity, glycolysis, and fatty-acid oxidation (79–
81). In healthy humans also, some data suggest that IH either at
rest or combined with exercise training can improve metabolic
status. In a single blind, randomized controlled trial, Haufe at
al. (82) have shown in 20 healthy lean subjects that performing
endurance training in hypoxia (60min of treadmill running, three
times a week during 4weeks, FiO2= 15%) compared to normoxia
(FiO2= 21%) at the same relative intensity elicit greater reduc-
tion in body fat mass as well as in circulating triglyceride and
fasting insulin levels. Interestingly, these effects were observed
despite of a smaller absolute workload during hypoxic exercise
training.
Intermittent hypoxia exposure can also significantly modify
appetite regulation. Bailey et al. (83) reported that a 3 h exposure
to normobaric hypoxia while performing a 50min exercise in 12
healthy males caused a suppression in appetite and a reduction
in plasma levels of acylated ghrelin concentrations, the hunger-
stimulating hormone.
Hypoxic Conditioning for Patients
Based on preclinical data as well as on studies in healthy subjects
showing potential positive effects of IH exposure, pilot investiga-
tions have been conducted in various pathological conditions to
assess the potential clinical application of hypoxic conditioning
(Table 1).
Cardiovascular Diseases
Hypertension and Vascular Function
Murine models have demonstrated the antihypertensive effect
of hypoxic conditioning as observed in spontaneously hyper-
tensive rats. This effect seems to be mediated, at least in part,
by NO metabolism, which may underlie hypoxia-induced pre-
vention of endothelial dysfunction, a well-known major risk for
hypertension (100–102). IH has been proposed as a mean to
treat hypertension in humans. Serebrovskaya et al. (102) high-
light in their review encouraging results reported in the Rus-
sian literature with noteworthy improvements in blood pressure
(e.g., a decrease of 10–30mmHg in systolic and 10–15mmHg
in diastolic blood pressure) following exposure to only a few
episodes of moderate hypoxia (FiO2= 10–14%) for a short dura-
tion (15min to 4 h per session) for 10–30 days. In a more recent
study, Lyamina et al. (85) exposed 37 young non-overweight
men with stage 1 hypertension to 20 sessions of 4 to 10 cycles
of 3-min hypoxia (FiO2= 10%) and 3-min room air breathing.
A significant decrease in blood pressure was observed follow-
ing the intervention with values in patients not different any-
more from the normotensive control group. Moreover, the reduc-
tion in blood pressure persisted for up to 3months in 28 ini-
tially hypertensive patients. Thus, considering the good tolerance
profile and apparently harmless aspect of moderate IH condi-
tioning protocols, it could be considered as an interesting and
promising adjunct therapeutic strategy to reduce systemic blood
pressure.
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TABLE 1 | Characteristics of hypoxic conditioning interventions in patients.
Author Subjects Conditioning stimulus
Duration Hypoxic intervention Control intervention Exercise/rest
CARDIOVASCULAR DISEASES
Burtscher
et al. (84)
16 elderly men
(50–70 years old, eight
with prior myocardial
infarction, and eight
without)
3weeks, 5 sessions a
week (15 sessions)
Three to five times 3-5min
hypoxia
(FiO2= 10–14%) – 3min
normoxia
Normoxia (3weeks of
exposure, five sessions
a week)
Rest
Lyamina
et al. (85)
37 young non-overweight
men with stage 1
hypertension (32 years old)
20 consecutive days,
one session a day
Four to 10 times 3min
hypoxia (FiO2= 10%) – 3min
normoxia
20 normotensive
participants (35 years
old), no exposure
Rest
NEUROLOGICAL DISEASES
Trumbower
et al. (86)
13 subjects with
incomplete SCI, ASIA
Score C or D
One single session 15 times 60 or 90 s hypoxia
(FiO2= 9%) – 60 s normoxia
Normoxia Rest
Schega
et al. (87)
34 healthy subjects
(60-70 years), cognitively
preserved
6weeks, 3 sessions a
week (18 sessions)
1 h/session, 10min hypoxia
(FiO2 adjusted to reach a
SpO2= 90% the first
2weeks, 85% the third week
and 80% the last three
weeks) – 5min normoxia
Normoxia 30min
strength-endurance
training after each
normoxia/hypoxia session
Hayes
et al. (88)
19 subjects with
incomplete chronic SCI,
ASIA Score C or D
5 consecutive days, one
session a day
15 times 90 s hypoxia
(FiO2= 9%) – 60 s normoxia
Normoxia Conditioning at rest or
combined with a 30-min
over-ground walking
training performed 1 h later
Tester et al.
(89)
Eight individuals with
cervical or thoracic
incomplete SCI, ASIA
Score ranging from A to D
10 consecutive days,
one session a day
Eight times 2min hypoxia
(FiO2= 8%) – 2min
normoxia, controlled end-tidal
CO2 level (2mmHg above
resting values)
Normoxia in a subset
of n= 4 subjects 1 day
before and 10days
after conditioning
Rest
VENTILATION/RESPIRATORY DISEASES
Aboubakr
et al. (90)
11 severe OSAS patients One night session during
non-rapid-eye
movement sleep before
and after 4weeks of
CPAP treatment
10 times 3min hypoxia
(FiO2= 8%) – 5min
normoxia, isocapnia
One-night normoxia,
subset of n= 7
Rest
Rowley
et al. (91)
13 OSAS patients One night session during
non-rapid-eye
movement sleep
10 times 3min hypoxia
(FiO2= 8%) – 5min
normoxia, isocapnia
One-night normoxia,
subset of n= 8
Rest
Burtscher
et al. (92)
18 eucapnic normoxic
mild COPD patients
3weeks, 5 sessions a
week (15 sessions)
3 to 5 times 3-5min hypoxia
(FiO2= 12-15%) – 3min
normoxia
Normoxia Rest
Haider
et al. (93)
18 eucapnic normoxic
mild COPD patients
3weeks, 5 sessions a
week (15 sessions)
Three to five times 3–5min
hypoxia
(FiO2= 12–15%) – 3min
normoxia
Normoxia
Age-matched healthy
controls, n= 14
Rest
METABOLIC DISEASES
Netzer
et al. (94)
20 obese subjects 8weeks, 3 sessions a
week (24 sessions)
90min hypoxia (FiO2= 15%) Normoxia,
sham-exposure
Stepper, treadmill and
bicycle ergometer-training
combined with
conditioning, without any
dietary intervention
Wiesner
et al. (95)
45 sedentary overweight
or obese subjects,
non-diabetic or
insulin-resistant
4weeks, 3 sessions a
week (12 sessions)
60min hypoxia (FiO2= 15%) Normoxia Treadmill-training
combined with
conditioning
Mackenzie
et al. (96)
Eight type 2 diabetic
patients
One single session 60min hypoxia (FiO2= 15%) Normoxia Four conditions for all
patients: Rest: hypoxia
and normoxia; Cycling:
hypoxia and normoxia
(Continued)
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TABLE 1 | Continued
Author Subjects Conditioning stimulus
Duration Hypoxic intervention Control intervention Exercise/rest
Mackenzie
et al. (97)
Eight type 2 diabetic
patients
One single 60, 40 and
20-min session,
combined with exercise
60, 40 and 20min hypoxia
(FiO2= 15%)
No control group 60, 40, and 20min cycling
Workman
and Basset
et al. (98)
15 sedentary overweight
males
One session. A subset of
n= 6 underwent
conditioning on 6
consecutive days
3 h hypoxia, targeted SpO2 
80%
3h normoxia Rest
Kong et al.
(99)
18 young obese subjects 4weeks, 3 sessions a
week, cumulative
exposure of 6 h/week
2 h hypoxia
(FiO2= 14.5-16.4%)
2 h normoxia Endurance and strength
training combined with a
low-calorie intake diet
ASIA, American Spinal Injury Association; COPD, chronic obstructive pulmonary disease; FiO2, fraction of inspired oxygen; h, hour(s); min, minute(s); Normoxia (FiO2=21%); OSAS,
obstructive sleep apnea syndrome; s, second(s); SCI, spinal cord injury; SpO2, peripheral capillary oxygen saturation.
Acute Myocardial Infarction
In addition to its potential effect on the vascular function and
blood pressure, hypoxic conditioning strategies may be useful to
improve heart function and prevent the early and delayed delete-
rious consequences of myocardial infarction. Forty days of hypo-
baric IH exposure before ligation of the left coronary artery in
mice reducedmyocardial infarct size andmortality rates (26). The
same intervention applied after ligation was also shown to reduce
the risk of arrhythmia occurrence (29). Normobaric IH protocols
induce the same effects, with reduced cardiac arrhythmias during
ischemia and decreased infarct size by 43% following ischemia-
reperfusion injury (103). However, in humans, since myocardial
infarction is not a predictable event, similar hypoxic precondition-
ing strategies using IH are actually difficult to implement.
Besides hypoxic conditioning, ischemic conditioning, consist-
ing in brief ischemic episodes, even remote (lower or upper limb
intermittent ischemia), can enhance myocardial tolerance to sub-
sequent ischemic or ischemia-reperfusion insults. Based on pre-
clinical remote or perioperative ischemic conditioning studies (17,
104), clinical studies have been conducted to evaluate the effect of
remote ischemic conditioning (RIC) in patients. In a randomized
controlled study, 333 consecutive adult patients with a suspected
first acute myocardial infarction were assigned to receive a pri-
mary percutaneous coronary intervention with (interventional
group, unilateral intermittent upper-arm ischemia, four cycles of
5min inflation up to 200mmHg and 5min deflation of a standard
upper-arm pressure cuff) or without (control group) prior RIC
during transport to hospital. In addition to the favorable safety
profile of RIC, a significant increase in myocardial salvage, an
established prognostic factor of mortality (105), has been shown
when RIC was applied (106). More recently, and using the same
study design and RIC paradigm in patients presenting with a ST-
segment elevation myocardial infarction, the group treated with
RIC prior to primary percutaneous coronary intervention showed
reducedmyocardial infarct size, increasedmyocardial salvage, and
reduced myocardial edema (107).
Chronic Coronary Artery Disease
The beneficial role of IH in chronic coronary artery disease has
also been considered (32). An augmented coronary collateral
vessel development has been reported in OSAS patients (apnea-
hypopnea index>10 events/h) (13) suggesting that somedegree of
IH may induce positive myocardial adaptations. In a prospective
controlled study in 16 elderly men (50–70 years old, eight with
prior myocardial infarction and eight without), subjects were
assigned randomly and in a double-blind fashion to moderate
IH [3weeks, 15 passive exposure sessions, three to five episodes
(3–5min) of hypoxia (FiO2= 10–14%) per session with 3-min
normoxic interval] or normoxia (control group, 3 weeks of expo-
sure). An increased peak-oxygen consumption following hypoxic
conditioning was shown both in subjects with and without prior
myocardial infarction compared to normoxic exposure (84). Fur-
thermore, heart rate, systolic blood pressure, blood lactate con-
centration, and the rating of perceived exertion during submax-
imal exercise (cycling at 1W/kg) were diminished in subjects
exposed to IH. Hence, IH exposure may be considered in chronic
coronary artery disease as a procedure to improve cardiovascular
parameters.
Heart Failure
Preclinical studies in healthy lean mice (108) and in a mice
model of heart failure (109) showed an improved cardiac func-
tion following 4weeks of exposure to IH. In patients with heart
failure, a syndrome resulting from several cardiac injuries, IH has
not been clinically tested yet, but encouraging results regarding
RIC are actually available. Kono et al. (110) reported increased
coronary flow reserve both in subjects with heart failure (n= 10)
and in healthy subjects (n= 10) following 1week of upper-limb
RIC (4 cycles of 5min inflation and 5min deflation of a blood
pressure cuff).
While current preclinical and clinical results suggest that
IH may be an innovative and non-pharmacological therapeutic
option in cardiovascular diseases, additional clinical studies are
required in patients with various cardiac conditions to confirm
the potential of hypoxic conditioning as a therapeutic tool.
Neurological Diseases
Stroke
The protective effects of hypoxic conditioning are not restricted
to the heart and may also apply to the brain. Remarkable clinical
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and preclinical data support the ability of hypoxic/ischemic con-
ditioning to enhance brain tolerance to ischemia. In humans,
retrospective studies (15, 16) or prospective studies (111) and
clinical evidence (112, 113) have reported lower severity and
better functional outcome following stroke in patients who have
previously experienced spontaneous transient ischemic attacks.
Despite some discrepancies (114–116), these findings suggest an
endogenous ischemic neuroprotective preconditioning triggered
by transient ischemic attacks. As for myocardial infarction, the
unpredictable nature of stroke actually restrains the clinical appli-
cability of hypoxic/ischemic preconditioning. Post-conditioning
might be a useful alternative paradigm. It refers to the appli-
cation of the conditioning stimulus after the occurrence of the
harmful event in order to treat or prevent its consequences. In
rodents, 7 days after transient mild cerebral artery occlusion,
exposure to moderate IH for 7 days induced hippocampal neu-
rogenesis, synaptogenesis, increased brain-derived neurotrophic
factor expression, and significantly improved functional outcomes
regarding spatial learning andmemory (117). RIC following acute
ischemic stroke has also been studied in preclinical (118) and
clinical (119) conditions alone or as an adjunct therapy to con-
ventional fibrinolysis with encouraging results in both cases. Since
hypoxic/ischemic conditioning seems to be harmless and rela-
tively easy to implement at bedside, it may represent a promising
adjunct therapy in stroke patients.
Spinal Cord Injury
Trumbower et al. (86) exposed, in a randomized controlled sin-
gle blind crossover trial, 13 incomplete spinal cord injury (SCI)
subjects to 15 repeated bouts of IH (60 or 90 s, FiO2= 9%),
separated by 60 s of normoxic exposure (FiO2= 21%). Hypoxic
sessions were compared to sessions in which subjects received
sham exposure (i.e., room air). Changes in maximum isometric
ankle plantar flexor torque generationwere significantly increased
by 82 33% immediately after IH exposure and were maintained
above baseline for more than 90min. Increased ankle plantar
flexor electromyogram activity was correlated with increased
torque (r2= 0.5, P< 0.001). There was no change from baseline
following sham experiments. Hayes et al. (88), in a random-
ized, double blind, placebo-controlled, crossover study, exposed
19 participants with chronic incomplete SCI to 15 repetitions
of 90 s hypoxic exposure (FiO2= 9%) interspersed by 60 s nor-
moxia or to normoxic exposure (FiO2= 21%, placebo) on five
consecutive days, alone or combined with 30min of over-ground
walking 1 h later. In this study, IH improved both walking
speed and endurance, and the impact of hypoxia exposure was
enhancedwhen combinedwith walking (88). Beyondmotor func-
tion enhancement, IH could also promote recovery of respiratory
motor function: a recent case study has outlined an improvement
in airflow in response to resistive loads applied in a 55-year-
old woman with chronic SCI following acute exposure to IH
(120). Furthermore, in a controlled trial, eight individuals with
either cervical (n= 6) or thoracic (n= 2) incomplete SCI were
exposed to IH [eight 2min hypoxic bouts (FiO2= 8%) inter-
spersed with a 2min recovery period (room air, FiO2= 21%)] for
10 consecutive days, with controlled end-tidal CO2 level (2mmHg
above resting values) (89). A subset of four participants received
additional sham exposure (room air). After each single IH session,
an increase in minute ventilation 30min after IH exposure was
observed, whereas no change was observed following sham expo-
sure to room air. These results occurred within the first 2 days of
IH exposure, and persisted throughout the 10 days of exposure to
IH. Themagnitude of ventilatory LTF remained enhanced 10 days
after the intervention in some (n= 2) but not all participants.
The effect of hypoxic conditioning in the field of cognitive
performances has also been explored in healthy older individu-
als. In a recent randomized controlled trial, 34 retired healthy
subjects (60–70 years), not physically active and cognitively pre-
served (MMSE> 27/30), were assigned either to a normoxic
group (control group, n= 17, targeted SpO2= 94–98%) or to a
hypoxic group (n= 17, alternating 10min hypoxia and 5min of
normoxia, FiO2 in hypoxia was adjusted to reach a SpO2= 90%
the first 2 weeks, 85% the third week, and 80% in the last 3 weeks
during hypoxia). Both groups were subjected to 1-h sessions (nor-
moxia/hypoxia), three times a week for 6weeks. Thirty minutes
strength-endurance training followed each normoxic/hypoxic
session. Combining IH exposure and exercise training enhanced
cognitive performance and quality of life to a greater extent than
exercise training alone (87).
On the basis of these clinical findings and according for
instance to promising results in animal models of Alzheimer’s
disease submitted to IH (121), further research is needed to eval-
uate the effect of IH exposure in neurological conditions and the
potential of hypoxic conditioning as a preventive or therapeutic
tool for these diseases. As physical activity, by triggering beneficial
neurovascular adaptations (122), hypoxic conditioning may be
a promising therapeutic strategy to prevent or slow down brain
aging.
Respiratory Diseases
Although exposing patients with respiratory illnesses to IH may
seem provocative, some data suggest that hypoxic conditioning
may also be considered for these patients.
Obstructive Sleep Apnea Syndrome
Considering OSAS patients, a decrease in upper airway resistance
following moderate IH protocol [11 subjects with severe OSAS,
exposed during non-rapid eye movement to 10 cycles of 3-min
hypoxia (FiO2= 8%) followed by 5min of room air] has been
shown, indicating a LTF of upper airway dilatators (90). The same
IH paradigm does not alter upper airway critical closing pressure
within the same population (91). This may support the use of
IH as an adjunct therapy in OSAS, in combination with other
conventional treatments (e.g., continuous positive airway pres-
sure), as suggested by Mateika et al. in their recent review (123).
Additional work is, however, required to optimize IH protocols
before translating it to therapeutic interventions.
Chronic Obstructive Pulmonary Disease
The effects of repetitive bouts of mild acute IH [15 sessions over
3weeks, three to five hypoxic bouts (FiO2= 12–15%), each lasting
3–5min, separated by 3min normoxic intervals], were evaluated
in 18 eucapnic normoxic mild chronic obstructive pulmonary
disease (COPD) patients according to a randomized controlled
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and double blind study design. Increased total hemoglobin mass,
exercise time to anaerobic threshold, and total exercise time were
demonstrated (92) as well as improved baroreflex sensitivity up
to normal levels and enhanced hypercapnic ventilatory response
without changes in hypoxic ventilatory response (93).
Metabolic Diseases
The use of IH to induce weight loss has been suggested since
hypoxia can increase energy expenditure (98, 124). Obese sub-
jects submitted to hypobaric hypoxia (1 week at 2650m) showed
weight loss, increased basal metabolic rate, and decreased food
intake (125). Combining hypoxic exposure with physical activ-
ity has been reported to potentiate weight loss. Netzer et al.
(94) randomly exposed 20 obese individuals (mean body mass
index= 33.1 kg/m2) to an 8-week training program (three 90min
sessions per week) at 60% of their individual maximal oxygen
uptake either in normobaric hypoxia (FiO2= 15%) or in nor-
moxia (sham, FiO2= 20.1%), without any dietary intervention.
Subjects in the hypoxic group lost significantly more weight (1.14
versus 0.03Kg) than the sham group. Wiesner et al. (95) sub-
mitted sedentary, non-diabetic or insulin-resistant, overweight or
obese subjects to a treadmill-training, 60min a day, thrice weekly
over a 4-week period at a heart rate corresponding to 65% of
theirmaximumoxygen uptake under normoxia (normoxic group,
n= 21, FiO2= 21%) or normobaric hypoxia (hypoxic group,
n= 24, FiO2= 15%). Both groups showed similar improvement
in maximal oxygen uptake, despite a smaller training workload in
the hypoxic group. Body composition improvedmore (i.e., greater
reduction in body-fat mass) in the hypoxic group. More recently,
Kong et al. (99) randomly assigned 22 young obese subjects
(17–25 years, body mass index >27.5 kg/m2) to either a normo-
baric hypoxic (FiO2= 16.4–14.5%, three 2 h sessions per week,
cumulative exposure of 6 h/week) or a normoxic (FiO2= 21%)
training for 4weeks. Combined with a low-calorie intake diet
and a strength-endurance training program, both groups exhib-
ited weight loss, but weight loss was significantly greater in the
hypoxic group. In addition, hypoxic exposure improved systolic
blood pressure and mean blood pressure. Taken together, these
arguments are supportive of IH as an adjunct therapy to enhance
weight loss in obese patients. In a recent review, Urdampilleta et al.
(126) proposed an IH conditioning protocol targeting both weight
loss and aerobic capacity improvement. This protocol would
consist in IH exposure three times per week, during 3–6weeks,
with a target FiO2 of 10–12%, with or without physical train-
ing (20–30min strength-resistance exercises and 30min high-
intensity aerobic exercise).
Based on preclinical data (127), hypoxic conditioning has been
tested in type 2 diabetes. Eight type 2 diabetic patients com-
pleted four 60-min sessions (interspersed by 7–14 days) of nor-
moxic rest, normoxic exercise, hypoxic rest, and hypoxic exercise
(FiO2= 14.6 0.4%) (41). Exercise intensity was set at 90% of
lactate threshold. Acute hypoxic exposure both at rest and during
exercise increased insulin sensitivity (96). In another study from
the same group, eight type 2 diabeticmales first performed 60min
of hypoxic exercise (FiO2= 14.7 0.2%, exercise intensity at 90%
of lactate threshold= 49 4 Watts) and then 40- and 20-min
exercise sessions at a higher intensity (at 70 9 and 140 12
Watts, respectively) to provide similar total workload. This proto-
col induced an acute- (24 h) and moderate-term (48 h) improve-
ment in insulin sensitivity following the 40- and 60-min hypoxic
exercise sessions. This emphasizes the role of exercise duration or
intensity (rather than the total workload completed) on glucose
control in type 2 diabetics (97). Although encouraging, the ben-
eficial effects of hypoxic conditioning for diabetic patients have
nonetheless to be further evaluated by additional clinical studies.
Remaining Questions and Perspectives for
Future Researches
Although the bench-based foundation for ischemic and hypoxic
conditioning is strong, the translation of conditioning strate-
gies into effective, validated therapies and clinical practice is
so far mostly missing. The above results reported in patients,
despite frequent important weakness in study design, suggest
several promising applications for hypoxic conditioning as a non-
pharmacological intervention for prevention or recovery in many
pathological conditions. To successfully address the challenge of
translating the strong experimental and preclinical data regard-
ing conditioning strategies into potential clinical applications,
several important issues have to be considered. Many questions
remain regarding the optimal conditioning stimulus, the most
favorable clinical setting to apply the conditioning phenomenon,
and whether a conditioning response can always be induced in
humans who, in contrast to laboratory animals, are elderly and
have multiple comorbidities. Since hypoxic conditioning is part
of a continuum from normoxia to deleterious severe hypoxia
(Figure 2), suitable biomarkers to identify in humans the occur-
rence of hypoxic conditioning are needed.
Various conditioning stimuli such as exposure to ischemia,
hypoxia, metabolic inhibition, or inflammation below the thresh-
old of damage have been tested mostly in animal models and in
some cases in humans. Several conditioning strategies involved
drug administration and were potentially associated with impor-
tant limitations in terms of clinical application due to tolerance
issues, potential adverse effects, and clinical approval. Conversely,
non-pharmacological ischemic or hypoxic conditioning strategies
provide reasonable safety/toxicity profiles and appear to be well
tolerated in patients. Among the non-pharmacological condition-
ing strategies, RIC (e.g., limb ischemia to induce organ protection)
has been mostly tested in recent large clinical studies. Although
hypoxic conditioning and RIC may induce some common mech-
anisms, these two attractive and relatively easy to implement
conditioning strategies have to be compared in order to determine
which one should be the most efficient and practical for the clinic.
Although preclinical studies demonstrated the striking ability
of preconditioning strategies to protect against ischemic injuries,
in most clinical settings demonstration of the therapeutic poten-
tial of preconditioning against major insults may not be readily
achievable. Stroke as well as cardiac arrest is mostly of unpre-
dictable nature, which makes clinical validation of anticipatory
treatment with preconditioning strategy difficult. In addition,
most preconditioning models induce short-term protection (i.e.,
<72 h), while more prolonged state of protection or regeneration
are needed for many clinical settings. Hence, clinical validation
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FIGURE 2 | Schematic representation of the continuum from normoxia to severe hypoxia including hypoxic exposure leading to hypoxic conditioning.
and application of new conditioning strategies inducing sustained
state of protection and regeneration such as prolonged hypoxic
conditioning may be most appropriate (i) to improve risk factors
for cardiovascular, metabolic, and neurological diseases in popu-
lations not yet presenting acute insults or advanced degenerative
diseases (e.g., older individuals), (ii) as an intervention aiming
to antagonize and even reverse degenerative processes associated
with chronic disorders (e.g., neurological disorders), and (iii) as
a regenerative treatment following acute ischemic insult (e.g.,
following infarct).
The dose response of a conditioning stimuli is thought to
range from no response at low intensities to a protected state at
higher intensities while a further increase in stimulus intensity
would cause tissue damage. The therapeutic range of conditioning
may be therefore relatively narrow. Although grouped within
the term hypoxic conditioning, the interventions used in the
human studies described above vary greatly in terms of hypoxic
exposure duration, frequency, and severity (Table 1). Since all
stimuli are defined by their frequency, magnitude, and duration,
optimal titration of the repetitive stimulus is critical in order to
provide proofs of concept and practical guidelines for hypoxic
conditioning.
Responses to conditioning stimuli might be specific to sex,
dependent on age, and affected by medical comorbidities. Large
inter-individual differences exist in the response to identical
hypoxic stimulus due to variations in oxygen regulated gene
expression. This was shown for VEGF and other downstream
genes of HIF-1, suggesting that the source of this variation resides
within the HIF system itself (128). There are also epigenetic
differences between individuals as well as environmental and life
style related variables that may affect the hypoxic conditioning
mechanisms. Titration to define the optimal individual dose of
hypoxia for subsequent hypoxic conditioning program may be
needed to obtain the largest benefits without adverse effects.
Appropriate titration of the conditioning stimulus will depend
on reliable and validated biomarkers that remain to be deter-
mined. It is therefore critical to identify suitable biomarkers and
most probably arrays of biomarkers to detect whether a con-
ditioning response is actually occurring or conversely whether
some deleterious consequences of IH are induced as well as to
distinguish responders and non-responders to a given condi-
tioning strategy. Further animal studies are needed to determine
such biomarkers specific to hypoxic conditioning, which should
subsequently be validated in humans.
There is an increasing number of commercially available
devices permitting hypoxic exposure. These devices use technolo-
gies to reduce inhaled oxygen concentrations from the normal
21% to below 10%. Exposure can be done by hypoxic breathing
through a mask or inside a confined space like tents or rooms
while resting, sleeping, or exercising. These products are however
mostly designed for athletes and healthy individuals. The use of
hypoxic conditioning as a therapeutic strategy in patients would
require the use of specific technologies permitting controlled, safe,
and inexpensive IH exposure. Although the technologies mostly
exist, their integration within validated and certified medical
devices represents an important challenge for a large-scale use of
hypoxic conditioning as a preventive and treatment strategy in
various clinical settings.
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